Alembic Pharmaceuticals Ltd.APLLTD₹1,104.00 +13.94%

Alembic Pharmaceuticals Ltd. surged on Monday, hitting an intraday high of ₹1,106.70, after receiving final approval from the US drug regulator for a key cancer treatment. The USFDA has cleared Alembic to sell a generic version of Doxil, a chemotherapy drug used to treat ovarian cancer, AIDS-related Kaposi’s sarcoma, and multiple myeloma.

Alembic will launch the drug—Doxorubicin Hydrochloride Liposome Injection—in two dosage formats (20 mg/10 mL and 50 mg/25 mL single-dose vials). The product is estimated to have an annual market size of about $29 million in the US, according to IQVIA.

This latest approval marks Alembic’s 201st final ANDA nod from the USFDA, bringing its cumulative total of US approvals to 224, including 23 tentative approvals. The milestone further consolidates Alembic’s strategy of building a robust pipeline in high-entry-barrier products.

About Alembic Pharmaceuticals

Founded in 1907, Alembic Pharmaceuticals is a leading Indian pharmaceutical company with operations spanning branded formulations in India and generics across key regulated markets. The company’s expanding product portfolio is backed by consistent investment in innovation and compliance, making it a key player in both domestic and global pharma markets.

Let’s take a look at its Factor Analysis scores:

Note: The stock price mentioned is as of 11:30 AM.

Disclaimer

Investments in securities market are subject to market risks, read all the related documents carefully before investing. This is for informational purposes and should not be considered as recommendations.

Kindly refer to  https://share.market/ for more details.

PhonePe Wealth Broking Private Limited is a member of NSE & BSE with SEBI Regn. No.: INZ000302639, Depository Participant of CDSL Depository with SEBI Regn. No.: IN-DP-696-2022, Research Analyst with SEBI Regn No: INH000013387, BSE RA Enlistment Number: 5887, and Mutual Fund distributor with AMFI Registration No: ARN- 187821. Member ID: BSE- 6756, NSE- 90226. 

Registration granted by SEBI, enlistment as Research Analyst, and Certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors